OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
EMERYVILLE, Calif., March 20, 2024 BUSINESS WIRE OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates. "2023 was a year of significant expansion of OmniAb's partnership base and pipeline programs as we continued to execute against our plan, while key partner programs made significant progress despite last year's sector-related headwinds. Partners exceeded our expectations regarding the number of new programs entering the clinic, with a total of six new entrants last year," said Matt Foehr, Chief Executive Officer of OmniAb. "In addition, we successfully launched two new technologies and expanded our business development function, now with a presence in the U.S., EU and Asia Pacific. We look forward to meaningful advancements in 2024 and in the coming years, as we are now staffed and resourced to efficiently leverage the future growth of the business." Fourth Quarter 202
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Should You Hold Immunovant (IMVT)? [Yahoo! Finance]Yahoo! Finance
- Here's Why You Should Add Immunovant (IMVT) to Your Portfolio [Yahoo! Finance]Yahoo! Finance
- What Makes Immunovant (IMVT) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $50.00 price target on the stock.MarketBeat
IMVT
Earnings
- 2/12/24 - Beat
IMVT
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- IMVT's page on the SEC website